» Articles » PMID: 26829320

Cre-dependent Selection Yields AAV Variants for Widespread Gene Transfer to the Adult Brain

Overview
Journal Nat Biotechnol
Specialty Biotechnology
Date 2016 Feb 2
PMID 26829320
Citations 526
Authors
Affiliations
Soon will be listed here.
Abstract

Recombinant adeno-associated viruses (rAAVs) are commonly used vehicles for in vivo gene transfer. However, the tropism repertoire of naturally occurring AAVs is limited, prompting a search for novel AAV capsids with desired characteristics. Here we describe a capsid selection method, called Cre recombination-based AAV targeted evolution (CREATE), that enables the development of AAV capsids that more efficiently transduce defined Cre-expressing cell populations in vivo. We use CREATE to generate AAV variants that efficiently and widely transduce the adult mouse central nervous system (CNS) after intravenous injection. One variant, AAV-PHP.B, transfers genes throughout the CNS with an efficiency that is at least 40-fold greater than that of the current standard, AAV9 (refs. 14,15,16,17), and transduces the majority of astrocytes and neurons across multiple CNS regions. In vitro, it transduces human neurons and astrocytes more efficiently than does AAV9, demonstrating the potential of CREATE to produce customized AAV vectors for biomedical applications.

Citing Articles

Progress in AAV-Mediated In Vivo Gene Therapy and Its Applications in Central Nervous System Diseases.

Wang S, Xiao L Int J Mol Sci. 2025; 26(5).

PMID: 40076831 PMC: 11899905. DOI: 10.3390/ijms26052213.


Development of a rabbit model for adrenoleukodystrophy: A pilot study on gene therapy using rAAV9.

Zhou X, Ma C, Zhang X, Xu X, Duan F, Kou M Mol Ther Nucleic Acids. 2025; 36(1):102469.

PMID: 40027885 PMC: 11872110. DOI: 10.1016/j.omtn.2025.102469.


Cell-penetrating peptide-grafted AAV2 capsids for improved retinal delivery via intravitreal injection.

Wang J, Cui M, Liu H, Guo P, McGowan J, Cheng S Mol Ther Methods Clin Dev. 2025; 33(1):101426.

PMID: 40027263 PMC: 11872077. DOI: 10.1016/j.omtm.2025.101426.


Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy.

Zwi-Dantsis L, Mohamed S, Massaro G, Moeendarbary E Viruses. 2025; 17(2).

PMID: 40006994 PMC: 11861813. DOI: 10.3390/v17020239.


Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group.

Cavazza A, Molina-Estevez F, Plaza Reyes A, Ronco V, Naseem A, Malensek S Mol Ther Nucleic Acids. 2025; 36(1):102457.

PMID: 39991472 PMC: 11847086. DOI: 10.1016/j.omtn.2025.102457.


References
1.
Guenthner C, Miyamichi K, Yang H, Heller H, Luo L . Permanent genetic access to transiently active neurons via TRAP: targeted recombination in active populations. Neuron. 2013; 78(5):773-84. PMC: 3782391. DOI: 10.1016/j.neuron.2013.03.025. View

2.
Dalkara D, Byrne L, Klimczak R, Visel M, Yin L, Merigan W . In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013; 5(189):189ra76. DOI: 10.1126/scitranslmed.3005708. View

3.
Yang B, Treweek J, Kulkarni R, Deverman B, Chen C, Lubeck E . Single-cell phenotyping within transparent intact tissue through whole-body clearing. Cell. 2014; 158(4):945-958. PMC: 4153367. DOI: 10.1016/j.cell.2014.07.017. View

4.
Betley J, Sternson S . Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits. Hum Gene Ther. 2011; 22(6):669-77. PMC: 3107581. DOI: 10.1089/hum.2010.204. View

5.
Calcedo R, Vandenberghe L, Gao G, Lin J, Wilson J . Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009; 199(3):381-90. PMC: 10826927. DOI: 10.1086/595830. View